General Meeting of April 19, 2022: Terms and conditions for making preparatory documents available
Paris,
4
April 2022
– 7:00 a.m. CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641), a company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, informs its shareholders that a Combined General Meeting of the Company will be held on Tuesday April 19, 2022 at 10 a.m. at the registered office of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris (75012).
The prior notice including the agenda and the text of the resolutions was published in BALO n°31 (Bulletin des Annonces Légales Obligatoires) dated March 14, 2022 and the notice of meeting was published in BALO n° 39 April 1, 2022 and in Paris Posters.
The information relating to the Combined General Meeting and referred to in Article R. 22-10-23 of the French Commercial Code can be consulted from today on the Pixium Vision website at the following address:
www.pixium-vision.com, “Investors” section, “General Meeting”.
Any shareholder may also request that the documents and information referred to in Articles R.225-81 and R.225-83 of the Commercial Code be sent to the Company.
Shareholders may also view the documents at the Company’s registered office located at 74 rue du Faubourg Saint Antoine in Paris (75012) for a period of 15 days preceding the General Meeting.
About Pixium Vision
Pixium Vision
creates a world of bionic vision to allow those who have lost their sight to recover their visual perception and gain autonomy. Pixium Vision’s bionic vision systems are associated with surgery and a period of rehabilitation. The Prima System Wireless Photovoltaic Subretinal Micro-Implant is in clinical testing in patients who initially lost sight due to retinal degeneration due to the dry form of age-related macular degeneration (dry AMD) . Pixium Vision works closely with academic partners and some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London , the Institute of Ocular Microsurgery (IMO) in Barcelona, the University hospital in Bonn and the UPMC in Pittsburgh (Pennsylvania, USA). The Company is EN ISO 13485 certified and has received the “Innovative Company” qualification from Bpifrance.
Forward-Looking Statements This press release contains forward-looking statements. Although the Company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For more information about the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the “Risk Factors” section. of the Company’s 2021 half-year financial report and other documents that the Company files with the AMF, available on the AMF’s website (www.amf-france.org) or on the Company’s website.
For more information:
http://www.pixium-vision.com/en
follow us on
@PixiumVision
;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
contacts
|
Pixium Vision Offer Nonhoff Financial director [email protected] +33 1 76 21 47 68 |
Relationships hurry LifeSci Advisors Sophie Baumont [email protected] +33 6 27 74 74 49 |
Investor Relations LifeSci Advisors Guillaume van Renterghem [email protected] +41 76 735 01 31 |
Attachment
Pixium_EGM220404_FINAL_FR V1